And study led by the Germans Trias i Pujol Hospital in Badalona has shown that adding a new antiviral to the current vaccination schedule against Covid-19could reduce mortality by 30% in admitted patients. The center has explained through a statement that the study published in ´The Lancet Respiratory Medicine´, concludes that the monoclonal antibody tixagevimab/cilgavimab, can be added to the treatment with remdesivir and dexamethasone, which is already administered in the hospitals.
In this clinical trial, it has been shown that this strategy is safeand although it does not shorten the recovery period of patients, it does lower mortality, especially in the most severe cases. In addition, this strategy has been shown to be safe, and although it does not shorten the recovery period of patients, it does reduce mortality, especially in the most severe cases. The research is in phase 3 and evaluates the potential of a single intravenous dose.
A single intravenous dose
In addition, this combination, unlike previous studies with other antibodies that lost efficacy against omicronthe currently predominant variant, “would retain its ability to block this variant of the virus in the doses administered.
The study carried out in 80 centers worldwide, had the participation of 150 people admitted to the plant and semi-critical units in Spain. Including a large number of patients from all over the world suggests that the results would be warrantablebecause no differences have been observed in the efficacy or safety of treatment according to comorbidity or “associated morbidity”, according to immunosuppression or vaccination status.
Currently, we are in a situation of rebound in cases by Covid-19 in Spain, this has made debate is reopened on the mandatory nature of the mask indoors. The Ministry of Health registered last week, with data provided by the autonomous communities, 84,146 new cases of coronavirus, of which 42,997 have occurred in people over 60 years of age.
–
